Maraviroc: all 119 studies that test it
Page 2 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected PatientsStatus unknownNCT00988780Not applicable
- The St. Marys and The Mater Switch StudyTerminatedNCT00981773Phase 4
- Pilot Assessment of Lopinavir/Ritonavir and MaravirocTerminatedNCT00981318Phase 4
- Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV SubjectsCompletedNCT00966329Phase 4
- Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune RestorationCompletedNCT00944541Phase 2
- IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected PatientsCompletedNCT00935480Phase 3
- Maraviroc in Immunological Non-Responder (INR) HIV-1-infected SubjectsCompletedNCT00884858Phase 4
- Maraviroc Immune Recovery StudyCompletedNCT00875368Phase 4
- Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese VolunteersCompletedNCT00821535Phase 1
- Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/EmtricitabineCompletedNCT00808002Phase 3
- Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1CompletedNCT00795444Phase 2
- A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult SubjectsCompletedNCT00783484Phase 1
- Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsWithdrawnNCT00782301Phase 4
- Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal TissueCompletedNCT00775294Phase 1
- Maraviroc 300 mg Twice Daily in HIV Negative Male VolunteersCompletedNCT00771823Phase 1
- Maraviroc Compassionate UseWithdrawnNCT00719823Phase 3
- Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With MaravirocCompletedNCT00703586Phase 1
- Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency VirusCompletedNCT00643643Phase 2
- Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency VirusCompletedNCT00634959Phase 2